Analysis
MapLight Therapeutics: Strong Balance Sheet Ahead of Crucial Phase 2 Readouts in Q3 2026
Executive Summary MapLight Therapeutics, Inc. has reported its financial and operational results for the fourth quarter and full fiscal year...